Expression of wild-type and noncleavable Fas ligand by tetracycline-regulated adenoviral vectors to limit intimal hyperplasia in vascular lesions.

Proliferation of vascular smooth muscle cells (VSMCs) and the infiltration of T cells and macrophages into vessel wall are considered to be important for intimal lesion formation after balloon angioplasty. Previous studies have shown that Fas ligand (FasL) gene transfer to balloon-injured vessels inhibits lesion formation by killing both proliferating VSMCs and infiltrating inflammatory cells. Here, we describe the construction and utility of a binary, tetracycline-regulated adenovirus system that provides controlled transgene expression in vitro and in vivo. In this system, optimal transgene expression required cotransfection with an adenovirus encoding the tetracycline-dependent trans-activator (rtTA) and induction with doxycycline hydrochloride (DOX), an analog of tetracycline. Using this system, adenovirus constructs were designed that allow regulated expression of wild-type FasL and a noncleavable mutant of FasL (FasL-NC). Transduction of FasL and FasL-NC induced similar extents of apoptosis in proliferating VSMCs in vitro in a manner that was dependent on the doses of the rtTA adenovirus and the presence of DOX in the medium. Furthermore, inhibition of intimal hyperplasia in injured carotid arteries by FasL or FasL-NC transduction was also dependent on cotransfection with the rtTA adenovirus and administration of DOX by subcutaneous injection. In contrast to wild-type FasL, transduction of FasL-NC did not result in the production of soluble (cleaved) FasL in the medium of infected cells in vitro, or in the serum of rats after local gene transfer to carotid arteries. In conclusion, this binary tetracycline-inducible adenovirus system may allow for safer delivery of cytotoxic genes for therapeutic purposes.

[1]  M. Gossen,et al.  Tight control of gene expression in mammalian cells by tetracycline-responsive promoters. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[2]  S. Nagata,et al.  Erratum: Lethal effect of the anti-Fas antibody in mice (Nature (1993) 364 (806-809)) , 1993 .

[3]  T. Murayama,et al.  Levels of soluble FasL and FasL gene expression during the development of graft‐versus‐host disease in DLT‐treated patients , 1999, British journal of haematology.

[4]  C. Koh,et al.  Serum levels of apoptosis-related molecules in patients with multiple sclerosis and human T-lymphotropic virus Type I-associated myelopathy. , 1999, Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research.

[5]  M. Leon,et al.  Small stent size and intimal hyperplasia contribute to restenosis: a volumetric intravascular ultrasound analysis. , 1995, Journal of the American College of Cardiology.

[6]  L. Turka,et al.  Amelioration of collagen-induced arthritis by CD95 (Apo-1/Fas)-ligand gene transfer. , 1997, The Journal of clinical investigation.

[7]  J. Tschopp,et al.  Melanoma Cell Expression of Fas(Apo-1/CD95) Ligand: Implications for Tumor Immune Escape , 1996, Science.

[8]  K. Walsh,et al.  TNFalpha regulation of Fas ligand expression on the vascular endothelium modulates leukocyte extravasation. , 1998, Nature medicine.

[9]  J. Tschopp,et al.  Conversion of Membrane-bound Fas(CD95) Ligand to Its Soluble Form Is Associated with Downregulation of Its Proapoptotic Activity and Loss of Liver Toxicity , 1998, The Journal of experimental medicine.

[10]  J. Uney,et al.  Switching transgene expression in the brain using an adenoviral tetracycline-regulatable system , 1998, Nature Biotechnology.

[11]  J. Uney,et al.  Tetracycline‐Regulated Transgene Expression in Hippocampal Neurones Following Transfection with Adenoviral Vectors , 1997, Journal of neurochemistry.

[12]  E J Topol,et al.  The restenosis paradigm revisited: an alternative proposal for cellular mechanisms. , 1992, Journal of the American College of Cardiology.

[13]  S. Nagata,et al.  The Fas death factor , 1995, Science.

[14]  Toshihiko Tanaka,et al.  Reducing supply current harmonics , 1998 .

[15]  M. Gossen,et al.  Transcriptional activation by tetracyclines in mammalian cells. , 1995, Science.

[16]  C. Logothetis,et al.  Development of an adenovirus vector with tetracycline-regulatable human tumor necrosis factor alpha gene expression. , 1997, Cancer research.

[17]  S. Yamamoto,et al.  Apoptosis by retrovirus- and adenovirus-mediated gene transfer of Fas ligand to glioma cells: implications for gene therapy. , 1998, Human gene therapy.

[18]  S. Yamaguchi,et al.  Elevated circulating levels and cardiac secretion of soluble Fas ligand in patients with congestive heart failure. , 1999, The American journal of cardiology.

[19]  K. Walsh,et al.  Oxidized LDL activates fas-mediated endothelial cell apoptosis. , 1998, The Journal of clinical investigation.

[20]  J. Mallet,et al.  A single adenovirus vector mediates doxycycline-controlled expression of tyrosine hydroxylase in brain grafts of human neural progenitors , 1999, Nature Biotechnology.

[21]  J. Isner,et al.  Histopathology of in-stent restenosis in patients with peripheral artery disease. , 1997, Circulation.

[22]  D. Green,et al.  Fas Ligand-Induced Apoptosis as a Mechanism of Immune Privilege , 1995, Science.

[23]  E. Pich,et al.  Highly controlled gene expression using combinations of a tissue-specific promoter, recombinant adenovirus and a tetracycline-regulatable transcription factor , 1998, Gene Therapy.

[24]  R. Ross.  The pathogenesis of atherosclerosis: a perspective for the 1990s , 1993, Nature.

[25]  S. Nagata,et al.  Elevation of the serum Fas ligand in patients with hemophagocytic syndrome and Diamond-Blackfan anemia. , 1998, Blood.

[26]  A. van der Eb,et al.  A new technique for the assay of infectivity of human adenovirus 5 DNA. , 1973, Virology.

[27]  K. Frei,et al.  Treatment of experimental glioma by administration of adenoviral vectors expressing Fas ligand. , 1999, Human gene therapy.

[28]  Y. Yazaki,et al.  Increased soluble Fas-ligand in sera of bone marrow transplant recipients with acute graft-versus-host disease , 1998, Bone Marrow Transplantation.

[29]  T. Libermann,et al.  Fas ligand gene transfer to the vessel wall inhibits neointima formation and overrides the adenovirus-mediated T cell response. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[30]  S. Nagata,et al.  Downregulation of Fas ligand by shedding , 1998, Nature Medicine.

[31]  Z. Wang,et al.  Induction of specific T-cell tolerance by adenovirus-transfected, Fas ligand-producing antigen-presenting cells , 1998, Nature Biotechnology.

[32]  A. Asai,et al.  Construction, propagation, and titer estimation of recombinant adenoviruses carrying proapoptotic genes. , 1998, Human gene therapy.

[33]  D. Green,et al.  Human lung carcinomas express Fas ligand. , 1997, Cancer research.

[34]  E. Nabel,et al.  Gene transfer of Fas ligand induces tumor regression in vivo. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[35]  Magnus Molin,et al.  Two Novel Adenovirus Vector Systems Permitting Regulated Protein Expression in Gene Transfer Experiments , 1998, Journal of Virology.

[36]  P. Lowenstein,et al.  FasL induces Fas/Apo1-mediated apoptosis in human embryonic kidney 293 cells routinely used to generate E1-deleted adenoviral vectors , 1998, Gene Therapy.

[37]  T. Libermann,et al.  Adenovirus-mediated expression of Fas ligand induces hepatic apoptosis after Systemic administration and apoptosis of ex vivo-infected pancreatic islet allografts and isografts. , 1997, Human gene therapy.

[38]  T. Ochi,et al.  Membrane Fas Ligand Kills Human Peripheral Blood T Lymphocytes, and Soluble Fas Ligand Blocks the Killing , 1997, The Journal of experimental medicine.

[39]  K. Ohshima,et al.  Elevated serum soluble Fas ligand in natural killer cell proliferative disorders , 1998, British journal of haematology.

[40]  H. Hamada,et al.  Adenovirus-mediated inducible gene expression through tetracycline-controllable transactivator with nuclear localization signal. , 1997, Biochemical and biophysical research communications.

[41]  K. Okumura,et al.  Soluble Fas (APO-1, CD95) and soluble Fas ligand in rheumatic diseases. , 1997, Arthritis and rheumatism.

[42]  D. Bellgrau,et al.  A role for CD95 ligand in preventing graft rejection , 1995, Nature.

[43]  K. Walsh,et al.  Adenovirus-mediated delivery of fas ligand inhibits intimal hyperplasia after balloon injury in immunologically primed animals. , 1999, Circulation.

[44]  A. H. Drummond,et al.  Fas ligand in human serum , 1996, Nature Medicine.

[45]  F. Marumo,et al.  Levels of soluble Fas ligand in myocarditis. , 1998, The American journal of cardiology.

[46]  M. Nobuyoshi,et al.  Restenosis after percutaneous transluminal coronary angioplasty: pathologic observations in 20 patients. , 1991, Journal of the American College of Cardiology.

[47]  R. Virmani,et al.  In vivo adenoviral vector-mediated gene transfer into balloon-injured rat carotid arteries. , 1993, Circulation research.

[48]  K. Walsh,et al.  Vascular endothelial cells and smooth muscle cells differ in expression of Fas and Fas ligand and in sensitivity to Fas ligand-induced cell death: implications for vascular disease and therapy. , 2000, Arteriosclerosis, thrombosis, and vascular biology.

[49]  F. Graham,et al.  Adenovirus-based expression vectors and recombinant vaccines. , 1992, Biotechnology.

[50]  D. D. Mosser,et al.  Inducible Overexpression of a Toxic Protein by an Adenovirus Vector with a Tetracycline-Regulatable Expression Cassette , 1998, Journal of Virology.

[51]  M. Sata,et al.  Endothelial Cell Apoptosis Induced by Oxidized LDL Is Associated with the Down-regulation of the Cellular Caspase Inhibitor FLIP* , 1998, The Journal of Biological Chemistry.

[52]  S. Nagata,et al.  Lethal effect of the anti-Fas antibody in mice , 1993, Nature.

[53]  B. Beutler,et al.  Cachectin and tumour necrosis factor as two sides of the same biological coin , 1986, Nature.